Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth

Background: The duration of protection after hepatitis B vaccination of infants is unknown. Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4–13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine. Those with nonprotective titers (<10 mIU/mL) received a booster dose. We similarly followed 16 children of hepatitis B surface antigen (HBsAg)-positive mothers. Results: Of low risk infants receiving a plasma-derived vaccine, 41% (42 of 102) of those whose primary response was unknown and 24% (4 of 17) who had initially responded retained protective titers (≥10 mIU/mL) of anti-HBs at 9 and 13 years, respectively. Of those who did not have protective antibody titers, 61% (33 of 54) and 67% (8 of 12), respectively, responded to a booster dose. In children of HBsAg-positive mothers, 31% retained protective anti-HBs at 12 years, and 90% (9 of 10) with nonprotective titers responded to a booster. In low risk children initially receiving a recombinant vaccine, 12.5% (26 of 208) and none (0 of 36) retained protective anti-HBs titers at 5 and 7 years of age, respectively. Of those who did not have protective titers, 90% (120 of 134) and 91% (32 of 35), respectively, responded to a booster. Conclusions: Anti-HBs disappeared by 5 years of age in most children who were vaccinated with hepatitis B vaccine from birth. Although most children showed immunologic memory, one-third failed to demonstrate an anamnestic response to a booster dose. Additional long term studies of low risk infants are needed to determine duration of protection and the necessity for or timing of booster doses.

[1]  B. McMahon,et al.  Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. , 1989, JAMA.

[2]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[3]  M. Yuen,et al.  Twelve‐year follow‐up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma‐derived vaccine without booster doses in children , 1999, Hepatology.

[4]  Mei-Hwei Chang,et al.  Long‐term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen , 1999, Hepatology.

[5]  V. Coronado,et al.  Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. , 2000, JAMA.

[6]  P. Shete,et al.  Real versus theoretical: assessing the risks and benefits of postponing the hepatitis B vaccine birth dose. , 2002, Pediatrics.

[7]  M. Pelliccia,et al.  Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. , 1997, Research in virology.

[8]  A. Osterhaus,et al.  Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines. , 2000, Vaccine.

[9]  Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). , 1991, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[10]  B. McMahon,et al.  Increases in levels of antibody to hepatitis B surface antigen in an immunized population. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Lauderdale,et al.  Hepatitis B vaccination among children in inner-city public housing, 1991-1997. , 1999, JAMA.

[12]  M. Curry,et al.  Immunobiology of Hepatitis Viruses , 2002 .

[13]  F. Mannelli,et al.  Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? , 1997, Vaccine.

[14]  B. McMahon,et al.  Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. , 1997, The Journal of infectious diseases.

[15]  W. Fetter,et al.  Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. , 1997, Vaccine.

[16]  M. Pelliccia,et al.  Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. , 1996, Vaccine.

[17]  H. Margolis,et al.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. , 2000, The Journal of infectious diseases.

[18]  D. West,et al.  Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. , 1994, The Pediatric infectious disease journal.

[19]  E. Yeoh,et al.  Five‐year follow‐up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma‐derived vaccine in children: Immunogenicity and anamnestic responses , 1993, Hepatology.

[20]  A. Faustini,et al.  Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. , 2001, Vaccine.

[21]  L. Hwang,et al.  Hepatitis B vaccination in high-risk infants: 10-year follow-up. , 1999, The Journal of infectious diseases.

[22]  D. West,et al.  Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. , 2002, The Pediatric infectious disease journal.

[23]  G. Calandra,et al.  Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. , 1996, Vaccine.